JP2013509411A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509411A5
JP2013509411A5 JP2012536862A JP2012536862A JP2013509411A5 JP 2013509411 A5 JP2013509411 A5 JP 2013509411A5 JP 2012536862 A JP2012536862 A JP 2012536862A JP 2012536862 A JP2012536862 A JP 2012536862A JP 2013509411 A5 JP2013509411 A5 JP 2013509411A5
Authority
JP
Japan
Prior art keywords
cancer
thiazole
indole
carbonyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012536862A
Other languages
English (en)
Japanese (ja)
Other versions
JP5598775B2 (ja
JP2013509411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052729 external-priority patent/WO2011053466A1/en
Publication of JP2013509411A publication Critical patent/JP2013509411A/ja
Publication of JP2013509411A5 publication Critical patent/JP2013509411A5/ja
Application granted granted Critical
Publication of JP5598775B2 publication Critical patent/JP5598775B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012536862A 2009-11-02 2010-10-14 癌の介入治療および根絶のためのiteとその類似体を含む医薬組成物 Expired - Fee Related JP5598775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25742209P 2009-11-02 2009-11-02
US61/257,422 2009-11-02
PCT/US2010/052729 WO2011053466A1 (en) 2009-11-02 2010-10-14 Ite for cancer intervention and eradication

Publications (3)

Publication Number Publication Date
JP2013509411A JP2013509411A (ja) 2013-03-14
JP2013509411A5 true JP2013509411A5 (enExample) 2013-10-10
JP5598775B2 JP5598775B2 (ja) 2014-10-01

Family

ID=43922453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012536862A Expired - Fee Related JP5598775B2 (ja) 2009-11-02 2010-10-14 癌の介入治療および根絶のためのiteとその類似体を含む医薬組成物

Country Status (9)

Country Link
US (6) US8604067B2 (enExample)
EP (2) EP3689347A1 (enExample)
JP (1) JP5598775B2 (enExample)
CN (2) CN102573470A (enExample)
AU (1) AU2010313622B2 (enExample)
CA (1) CA2776319C (enExample)
ES (1) ES2791684T3 (enExample)
NZ (2) NZ599896A (enExample)
WO (1) WO2011053466A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
EP3689347A1 (en) 2009-11-02 2020-08-05 Ariagen, Inc. Ite for cancer intervention and eradication
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
NZ728643A (en) 2014-09-12 2020-04-24 Ariagen Inc Efficient and scalable synthesis of 2-(1’h-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
EP3274053A4 (en) 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
TWI674260B (zh) * 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
JP2021503498A (ja) * 2017-11-20 2021-02-12 アリアジェン,インコーポレイテッド アリール炭化水素受容体(ahr)調節剤としてのインドール化合物
CN113906021A (zh) * 2019-04-15 2022-01-07 阿里根公司 手性吲哚化合物及其用途
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands
WO2021127302A1 (en) 2019-12-20 2021-06-24 Ikena Oncology, Inc. 2-(1h-indole-3-carbonyl)-thiazole-4-carboxamide derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders
JP2023508909A (ja) 2019-12-20 2023-03-06 イケナ オンコロジー, インコーポレイテッド 例えば血管新生関連障害または炎症性疾患の処置に向けたアリール炭化水素受容体(ahr)アゴニストとしての4-フェニル-n-(フェニル)チアゾール-2-アミン誘導体及び関連化合物
CN111067895A (zh) * 2020-01-14 2020-04-28 广东医科大学 Ite在制备预防和/或治疗心肺循环系统疾病的药物中的应用
WO2022133480A1 (en) 2020-12-18 2022-06-23 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
US20230391783A1 (en) * 2021-05-27 2023-12-07 Shandong University Compound containing 2,4-thiazole ring, preparation method therefor, and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
US7419992B2 (en) 2001-02-14 2008-09-02 Wisconsin Alumni Research Foundation Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
CA2437579C (en) 2001-02-14 2012-05-01 Hector F. Deluca Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
ATE394373T1 (de) 2002-02-12 2008-05-15 Wisconsin Alumni Res Found Synthese von indolthiazolverbindungen als liganden des ah-rezeptors
US7135488B2 (en) 2003-01-02 2006-11-14 Hoffmann-La Roche Inc. Pyrrolyl-thiazole derivatives
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
JP2011503232A (ja) * 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
EP2276833A4 (en) * 2008-03-21 2011-06-29 Brigham & Womens Hospital MODULATION OF THE IMMUNE RESPONSE
EP3689347A1 (en) 2009-11-02 2020-08-05 Ariagen, Inc. Ite for cancer intervention and eradication
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
CN103827094B (zh) 2011-08-26 2017-09-26 南方研究所 Hiv复制抑制剂
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives

Similar Documents

Publication Publication Date Title
JP2013509411A5 (enExample)
JP2023002662A5 (enExample)
JP2013522326A5 (enExample)
JP2015524444A5 (enExample)
JP2012520866A5 (enExample)
JP2014528901A5 (enExample)
JP2013542247A5 (enExample)
JP2013519645A5 (enExample)
JP2019503365A5 (enExample)
JP2014515373A5 (enExample)
JP2010505850A5 (enExample)
JP2012532874A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2013522303A5 (enExample)
RU2014121065A (ru) Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение
JP2009536191A5 (enExample)
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2013541583A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2011046708A5 (enExample)
TWI669113B (zh) 用於治療癌症之氧烯洛爾(oxprenolol)組合物
JP2014512355A5 (enExample)
JP2015508765A5 (enExample)